eCOA

Bridge the gap between data complexity and operational efficiency

IQVIA eCOA delivers unparalleled data quality, integrity and patient compliance to optimize your data collection. Experience an eCOA platform that provides accelerated pathways to market with transformative decisions fueled by real-time insights.
IQVIA eCOA captures data in real time to accelerate decision-making.
Our eCOA solution does all the heavy lifting to ensure your primary endpoints are achieved. With real-time data capture, autogenerated regulatory and project documentation and streamlined workflows, IQVIA eCOA will help you reduce implementation timelines by up to 75%.

An eCOA solution designed for you, built for your patients.

IQVIA eCOA is purpose-built to support the evolving demands of modern clinical research, combining scientific credibility, global scalability and advanced digital innovation. Our eCOA solution enables confident decision-making by delivering high-quality, regulatory-ready data through a seamless and patient-centric experience. With deep therapeutic expertise and a proven global footprint, IQVIA eCOA accelerates study timelines, enhances data integrity and ensures operational excellence across every phase of your trial. Explore how below:

DISCOVER WHY PALVELLA THERAPEUTICS QUICKLY BENEFITED FROM DEPLOYING IQVIA eCOA
IQVIA and Palvella Therapeutics: Why IQVIA?

Overview: IQVIA accelerates performance excellence in obesity trials

IQVIA helped accelerate performance excellence in obesity trials by combining scientific expertise, digital technology, including eCOA solutions and end-to-end support. The platform achieved over 90% patient compliance, improved data quality by 50% and reduced setup timelines by up to 75%, enabling sponsors to run faster, more efficient, and regulator-ready studies.
In response to the rapidly growing obesity drug market, IQVIA delivered a comprehensive solution that streamlined trial execution and enhanced data integrity. By integrating scientific strategy, preapproved obesity assessments within eCOA and connected device support, IQVIA enabled sponsors to design and implement trials with speed and precision. The platform’s automation features, such as real-time alerts triggered by glucometer readings, minimized patient burden and ensured timely, accurate data capture. IQVIA’s agile ecosystem supported adaptive trial designs and faster database lock timelines, driving deeper insights and proactive decision-making. Over the past five years, IQVIA has supported more than 80 obesity trials across 45 countries, enrolling over 60,000 patients. The result: a one-stop shop for high-performance, compliant obesity trials that deliver measurable impact.
Challenge

Challenge: Navigating Complexity in a Rapidly Growing Obesity Market

With the global obesity drug market surpassing $30 billion in 2024, sponsors face mounting pressure to run fast, efficient and regulator-ready trials. They must navigate complex trial designs, ensure high-quality data collection through eCOAs and adapt quickly to protocol changes—all while maintaining scientific rigor and compliance.
The obesity drug market is expanding rapidly, creating intense demand for clinical trials that are both scientifically sound and operationally agile. Sponsors must manage multifaceted challenges, including designing effective trial strategies, selecting appropriate outcome assessments and ensuring data accuracy and timeliness. eCOAs play a critical role, but they must be flexible enough to accommodate protocol changes and deliver regulator-ready data. Speed and innovation are essential, as sponsors strive to differentiate their products and meet evolving regulatory expectations. The complexity of obesity trials—often involving comorbidities and diverse endpoints—requires a strategic, integrated approach to trial design and execution. IQVIA’s solution addresses these needs by combining scientific expertise, digital technology and end-to-end support to streamline the entire trial lifecycle.
Solution

End-to-End Innovation for Smarter Obesity Trial Execution

IQVIA delivered an integrated, end-to-end solution for obesity trials, combining scientific strategy, eCOA technology and connected device support. Their agile platform accelerated setup timelines by up to 75%, improved data quality by 50% and achieved over 90% patient compliance—ensuring trials were efficient, compliant and regulator-ready.
IQVIA’s solution brought together scientific expertise, digital innovation and operational support to streamline obesity trial execution. Their team of seasoned advisors guided sponsors through endpoint strategy, instrument selection and regulatory alignment, ensuring scientifically sound and compliant trial designs. The eCOA platform was built with agility in mind, enabling rapid setup and seamless integration with connected devices like glucometers, which automatically triggered relevant assessments based on patient data. IQVIA’s preapproved library of obesity-related assessments further accelerated study builds. The platform’s automation and real-time monitoring capabilities reduced patient burden, improved data accuracy and supported adaptive trial designs. With over 80 obesity trials supported across 45 countries, IQVIA’s comprehensive approach delivered measurable improvements in trial performance and data quality.
Results

Driving Performance Excellence in Obesity Research

IQVIA’s comprehensive solution delivered measurable impact across obesity trials, achieving over 90% patient compliance and improving data quality by 50%. Their agile platform expedited COA strategies by up to 40% and reduced eCOA setup timelines by as much as 75%, supporting faster, more efficient trial execution.
IQVIA’s eCOA platform significantly enhanced trial performance in obesity studies, achieving over 90% patient compliance with diaries and improving data quality by 50%. The solution accelerated COA measurement strategies by up to 40% and reduced eCOA setup timelines by up to 75%, enabling faster trial starts and more efficient execution. Integrated connected devices, such as glucometers, automatically triggered relevant assessments based on patient data, reducing manual entry and ensuring timely event capture. An automated dashboard monitored trends and risks, allowing for proactive issue resolution. The platform’s agility supported adaptive trial designs and faster database lock timelines, streamlining final endpoint analysis. Over the past five years, IQVIA has supported more than 80 obesity trials across 45 countries, enrolling over 60,000 patients at more than 2,000 sites.
Read the full case study now
Contact Us